Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
- Conditions
- Infections, Gram-positive Bacterial
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT00077675
- Locations
- 🇺🇸
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
- Conditions
- CellulitisAbscessBurnsInfections, Gram-Positive BacterialUlcerWound Infections
- Interventions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 169
- Registration Number
- NCT00061633
- Locations
- 🇺🇸
eStudy Site, 3450 Bonita Road, Ste 201, Chula Vista, California, United States
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
- Conditions
- Pneumonia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00050401
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
- Conditions
- Bacterial InfectionsGram-Positive Bacterial InfectionsBacteremia
- First Posted Date
- 2002-05-15
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 739
- Registration Number
- NCT00037050
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00035425
- Locations
Pfizer Investigational Site
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.